Evolution of Multidrug Resistance in Plasmodium falciparum: a Longitudinal Study of Genetic Resistance Markers in the Greater Mekong Subregion
Open Access
- 17 November 2021
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 65 (12), e0112121
- https://doi.org/10.1128/aac.01121-21
Abstract
Increasing resistance in Plasmodium falciparum to artemisinins and their artemisinin combination therapy (ACT) partner drugs jeopardizes effective antimalarial treatment. Resistance is worst in the Greater Mekong subregion. Monitoring genetic markers of resistance can help to guide antimalarial therapy. Markers of resistance to artemisinins (PfKelch mutations), mefloquine (amplification of P. falciparum multidrug resistance-1 [PfMDR1]), and piperaquine (PfPlasmepsin2/3 amplification and specific P. falciparum chloroquine resistance transporter [PfCRT] mutations) were assessed in 6,722 P. falciparum samples from Vietnam, Lao People's Democratic Republic (PDR), Cambodia, Thailand, and Myanmar between 2007 and 2019. Against a high background prevalence of PfKelch mutations, PfMDR1 and PfPlasmepsin2/3 amplification closely followed regional drug pressures over time. PfPlasmepsin2/3 amplification preceded piperaquine resistance-associated PfCRT mutations in Cambodia and reached a peak prevalence of 23/28 (82%) in 2015. This declined to 57/156 (38%) after first-line treatment was changed from dihydroartemisinin-piperaquine to artesunate-mefloquine (ASMQ) between 2014 and 2017. The frequency of PfMDR1 amplification increased from 0/293 (0%) between 2012 and 2017 to 12/156 (8%) in 2019. Amplification of PfMDR1 and PfPlasmepsin2/3 in the same parasites was extremely rare (4/6,722 [0.06%]) and was dispersed over time. The mechanisms conferring mefloquine and piperaquine resistance may be counterbalancing. This supports the development of ASMQ plus piperaquine as a triple artemisinin combination therapy.Funding Information
- Wellcome (101148/Z/13/Z)
This publication has 32 references indexed in Scilit:
- A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype–genotype association studyThe Lancet Infectious Diseases, 2016
- Declining Efficacy of Artemisinin Combination Therapy AgainstP. FalciparumMalaria on the Thai–Myanmar Border (2003–2013): The Role of Parasite Genetic FactorsClinical Infectious Diseases, 2016
- Dihydroartemisinin–piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort studyThe Lancet Infectious Diseases, 2016
- Plasmodium falciparum dihydroartemisinin-piperaquine failures in Cambodia are associated with mutant K13 parasites presenting high survival rates in novel piperaquine in vitro assays: retrospective and prospective investigationsBMC Medicine, 2015
- Spread of Artemisinin Resistance in Plasmodium falciparum MalariaThe New England Journal of Medicine, 2014
- Plasmodium falciparum pfmdr1 Amplification, Mefloquine Resistance, and Parasite FitnessAntimicrobial Agents and Chemotherapy, 2009
- Genetic association analysis of copy-number variation (CNV) in human disease pathogenesisGenomics, 2009
- Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy numberThe Lancet, 2004
- Risk factors for gametocyte carriage in uncomplicated falciparum malaria.The American Journal of Tropical Medicine and Hygiene, 1999
- Point mutations in the dihydrofolate reductase-thymidylate synthase gene and pyrimethamine and cycloguanil resistance in Plasmodium falciparumMolecular and Biochemical Parasitology, 1995